TENX NASDAQ
Tenax Therapeutics, Inc.
1W: +5.5%
1M: -7.0%
3M: -88.4%
YTD: -84.4%
1Y: -76.7%
3Y: -92.7%
5Y: -99.9%
$1.72
+0.08 (+4.88%)
Pre-Market: $1.73 (+0.01, +0.87%)
Weekly Expected Move ±12.3%
$1
$2
$2
$2
$2
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' 6.52.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-01-28
Earliest Filing
2025-09-09
Latest Filing
partner: 5
acquirer: 1
investor: 1
Counterparties (Filed by TENX)
7 relationshipsCompanies named in TENX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Orion Corporation | ORN | partner | Licensee and supplier of levosimendan under an amended agreement | 2025-09-09 | View |
| Orion Corporation | ORN | partner | Licensee under an amended agreement for levosimendan-based products | 2024-02-20 | View |
| Roth Capital Partners, LLC | — | partner | Placement agent for the public offering | 2024-02-12 | View |
| Direct Transfer LLC | — | partner | Transfer agent for the common warrants | 2024-02-12 | View |
| Tenax Therapeutics, Inc. | TENX | acquirer | Company subject to the waiver of director appointment rights. | 2022-06-16 | View |
| Armistice Capital Master Fund Ltd. | — | investor | Master Fund that waived its right to appoint directors to the Company's Board. | 2022-06-16 | View |
| Orion Corporation | ORN | partner | Amendment to License Agreement extending term and defining supply obligations | 2022-01-28 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-08 | Other Events; Exhibits | View | |
| 2026-09-09 | Regulation FD; Exhibits | View | |
| 2026-08-10 | Other Events; Exhibits | View | |
| 2026-07-31 | Earnings Release; Exhibits | View | |
| 2026-07-02 | Other Events; Exhibits | View | |
| 2026-06-30 | Material Agreement; Exhibits | Agreement | View |
| 2026-06-29 | Officer/Director Change; Other Events; Exhibits | View | |
| 2026-06-04 | Shareholder Vote | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-04-22 | Officer/Director Change; Other Events; Exhibits | View | |
| 2026-03-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-09 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-12-17 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-16 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-09 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-17 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR